📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. (2014)

First Author: Salloway S

Attributed to: Further defining the genetic architecture of Alzheimer's disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa1304839

PubMed Identifier: 24450891

Publication URI: http://europepmc.org/abstract/MED/24450891

Type: Journal Article/Review

Volume: 370

Parent Publication: The New England journal of medicine

Issue: 4

ISSN: 0028-4793